Theravance 2025 Q3 Earnings 128.5% Net Income Surge Drives Profitability

Theravance (TBPH) delivered a historic turnaround in Q3 2025, posting a 128.5% net income improvement and 18.5% revenue growth. The results far exceeded expectations, with the company achieving non-GAAP breakeven and a $333 million cash balance. Guidance was not explicitly adjusted, but management reiterated confidence in maintaining breakeven performance through Q4.

Revenue

Theravance's revenue surged to $19.99 million in Q3 2025, driven entirely by the Viatris collaboration agreement, which accounted for the full amount of the quarter's total revenue. This represents an 18.5% increase from $16.87 million in the prior-year period, underscoring the strategic value of the partnership.

Earnings/Net Income

The company returned to profitability with an EPS of $0.07, reversing a $0.26 loss in 2024 Q3. Net income reached $3.62 million, a 128.5% positive swing from a $12.70 million loss. This remarkable turnaround reflects disciplined cost management and strong revenue leverage.

Price Action

Theravance's stock price demonstrated robust post-earnings momentum, rising 1.93% in the latest trading day, 20.71% over the past week, and 29.60% month-to-date. The upward trajectory aligns with positive analyst sentiment, including a 33.33% price target increase from HC Wainwright to $20.00.

**

**

**

**

Post-Earnings Price Action Review

Theravance's shares experienced a sustained rally following the Q3 earnings release, with a 1.93% intraday gain and a 20.71% weekly surge. Month-to-date, the stock climbed 29.60%, reflecting strong investor confidence in the company's profitability and pipeline catalysts. Analysts highlighted the $75 million in near-term milestone payments and the CYPRESS trial's potential as key drivers. Despite insider selling of 59,000 shares by Director Broshy, market sentiment remains overwhelmingly positive, supported by a revised "Buy" rating from HC Wainwright and a $20.00 price target.

CEO Commentary

CEO Rick Winningham emphasized, "Theravance delivered strong results in Q3, reflecting continued execution across the business and notable progress toward strategic objectives." He highlighted YUPELRI's record profitability, the $75 million in pending milestones, and the CYPRESS trial's potential as a "material value inflection point." Winningham reiterated the company's focus on disciplined capital allocation and operational execution.

Guidance

Management confirmed Q4 results will remain "broadly consistent" with Q3, excluding the $75 million in milestones. Non-GAAP breakeven is expected to continue, with operating expenses and share-based compensation projected to remain stable. The CYPRESS trial's Q1 2026 data readout remains the primary near-term catalyst.

Additional News

1. Insider Trading: Director Eran Broshy sold 59,000 shares ($1.1M) via a prearranged trading plan on Nov 11, 2025.

2. Analyst Upgrades: HC Wainwright raised TBPH's price target to $20.00 (+33.33%) while maintaining a "Buy" rating.

3. Pipeline Catalysts: Theravance outlined $75M in near-term milestones, including $25M from Viatris in Q4 and $50M for TRELEGY in Q4, with CYPRESS trial data expected in Q1 2026.